AIDS Treatment News logo      

July 21, 2010

New ViiV Integrase Inhibitor Effective Against Some Isentress-Resistant HIV Strains - by David Evans

POZ - POZ Magazine - "An experimental integrase inhibitor being developed by Shionogi Pharmaceuticals and ViiV Healthcare—currently dubbed S/GSK-572—effectively reduces HIV levels in at least some people with HIV resistant to Isentress (raltegravir). These findings were reported in a presentation Monday, July 19, at the International AIDS Conference (IAC), taking place July 18 to 23 in Vienna."